pyrazinamide has been researched along with AIDS-Related Opportunistic Infections in 52 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection." | 9.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "To characterize the susceptibility to levofloxacin of clinical isolates of Mycobacterium tuberculosis (MTB) obtained from patients with HIV-related tuberculosis and to characterize the molecular genetics of levofloxacin resistance." | 9.08 | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica ( Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE, 1997) |
| "To compare the efficacy of an intermittent 6-month regimen (Reg6M: 2EHRZ(3)/4HR(3) [ethambutol, 1,200 mg; isoniazid, 600 mg; rifampicin, 450 or 600 mg depending on body weight <60 or > or =60 kg; and pyrazinamide, 1,500 mg for 2 mo; followed by 4 mo of isoniazid and rifampicin at the same doses]) versus a 9-month regimen (Reg9M: 2EHRZ(3)/7HR(3)) in HIV/tuberculosis (TB)." | 5.14 | Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. ( Chinnaiyan, P; Iliayas, S; Menon, PA; Narayanan, PR; Narendran, G; Padmapriyadarsini, C; Ramachandran, R; Sakthivel, R; Santhanakrishnan, R; Suhadev, M; Swaminathan, S; Venkatesan, P, 2010) |
| "To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection." | 5.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "To test the hypothesis that antituberculous drug disposition is altered in patients with AIDS, we studied the steady-state pharmacokinetics of isoniazid (300 mg/d), rifampin (600 mg/d), and pyrazinamide (1,500 mg/d) in 29 adults (14 patients infected with human immunodeficiency virus [HIV] and 15 non-HIV-infected patients) with tuberculosis in Nairobi, Kenya." | 5.08 | Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. ( Aoki, FY; Choudhri, SH; Gathua, S; Hawken, M; Long, R; Minyiri, GO; Sahai, J; Sitar, DS; Watkins, W, 1997) |
| "To characterize the susceptibility to levofloxacin of clinical isolates of Mycobacterium tuberculosis (MTB) obtained from patients with HIV-related tuberculosis and to characterize the molecular genetics of levofloxacin resistance." | 5.08 | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica ( Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE, 1997) |
| "Isoniazid prophylaxis for 12 months effectively prevents tuberculosis in HIV-infected persons and may decrease the incidence of other HIV-related disease and mortality." | 3.70 | Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. ( Rose, DN, 1998) |
| "Study results presented at the 5th Conference on Retroviruses and Opportunistic Infections showed that a two-month regimen of rifampin with pyrazinamide proved to be as effective as a twelve-month regimen of isoniazid in the prevention of tuberculosis (TB) in HIV-positive individuals." | 3.70 | A short two-drug regimen prevents active TB. ( Torres, G, 1998) |
| "Substituted pyrazinoic acid esters have previously been reported to have in vitro activity against Mycobacterium avium and Mycobacterium kansasii as well as Mycobacterium tuberculosis." | 3.69 | Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. ( Bergmann, KE; Cynamon, MH; Welch, JT, 1996) |
| "Tuberculosis was associated with an increased mortality (adjusted rate ratio 1." | 2.70 | Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. ( Fuchs, D; Godfrey-Faussett, P; Hosp, M; Lisse, I; Mwinga, A; Quigley, MA, 2001) |
| "Treatment of tuberculosis has three major goals: healing the patient, preventing selection of resistant strains and control transmission of tuberculosis." | 2.40 | [Antitubercular chemotherapy]. ( Dautzenberg, B; Jouveshomme, S, 1997) |
| "Optimum treatment of tuberculosis in persons with human immunodeficiency virus (HIV) infection is still being defined." | 2.38 | Failure of therapy for tuberculosis in human immunodeficiency virus infection. ( Nolan, CM, 1992) |
| "All cases had evidence of pulmonary tuberculosis." | 1.33 | Ocular tuberculosis in acquired immunodeficiency syndrome. ( Babu, RB; Biswas, J; Kumarasamy, N; Sudharshan, S; Therese, L, 2006) |
| "Isoniazid resistance was more likely in HIV seronegative patients with M." | 1.30 | Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. ( Borgdorff, MW; Bretzel, G; Bwire, R; Kawuma, HJ; Rieder, HL; Rüsch-Gerdes, S; Sticht-Groh, V, 1999) |
| " Results show that RIF/PZA, dosed either daily or twice weekly, is as effective in preventing tuberculosis in dually-infected adults, as INH/pyridoxine given for 6-12 months." | 1.30 | Short course preventive therapy for tuberculosis is successful in HIV-infected patients. ( Chaisson, RE, 1998) |
| "There are few reports of children with AIDS and TB." | 1.29 | Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. ( Birnbaum, J; Chan, SP; Rao, M; Steiner, P, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 34 (65.38) | 18.2507 |
| 2000's | 14 (26.92) | 29.6817 |
| 2010's | 3 (5.77) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, L | 1 |
| Ye, Z | 1 |
| Liu, H | 1 |
| Guo, H | 1 |
| Lin, J | 1 |
| Zheng, L | 1 |
| Chu, N | 1 |
| Liu, X | 1 |
| Salinas, A | 1 |
| Martínez, E | 1 |
| Puerta, A | 1 |
| Nam-Cha, S | 1 |
| Swaminathan, S | 2 |
| Narendran, G | 1 |
| Venkatesan, P | 1 |
| Iliayas, S | 2 |
| Santhanakrishnan, R | 1 |
| Menon, PA | 1 |
| Padmapriyadarsini, C | 2 |
| Ramachandran, R | 1 |
| Chinnaiyan, P | 1 |
| Suhadev, M | 1 |
| Sakthivel, R | 1 |
| Narayanan, PR | 2 |
| Massongo, M | 1 |
| Pasquet, A | 1 |
| Huleux, T | 1 |
| Aïssi, E | 1 |
| Ettahar, N | 1 |
| Yazdanpanah, Y | 1 |
| Melliez, H | 1 |
| Roehr, B | 1 |
| Narita, M | 1 |
| Kellman, M | 1 |
| Franchini, DL | 1 |
| McMillan, ME | 1 |
| Hollender, ES | 1 |
| Ashkin, D | 1 |
| Chakaya, JM | 1 |
| Kibuga, D | 1 |
| Ng'ang'a, L | 1 |
| Githui, WA | 1 |
| Mansoer, JR | 1 |
| Gakiria, G | 1 |
| Kwamanga, D | 1 |
| Maende, J | 1 |
| Phyu, S | 1 |
| Ti, T | 1 |
| Jureen, R | 1 |
| Hmun, T | 1 |
| Myint, H | 1 |
| Htun, A | 1 |
| Grewal, HM | 1 |
| Bjorvatn, B | 1 |
| Babu, RB | 1 |
| Sudharshan, S | 1 |
| Kumarasamy, N | 1 |
| Therese, L | 1 |
| Biswas, J | 1 |
| Zhang, Y | 1 |
| Sukumar, B | 1 |
| Kumar, SR | 1 |
| Triveni, C | 1 |
| Gomathy, P | 1 |
| Thomas, B | 1 |
| Mathew, M | 1 |
| Okwera, A | 3 |
| Whalen, C | 1 |
| Byekwaso, F | 1 |
| Vjecha, M | 1 |
| Johnson, J | 1 |
| Huebner, R | 3 |
| Mugerwa, R | 1 |
| Ellner, J | 1 |
| Schrappe, M | 1 |
| Wassermann, K | 1 |
| Kroegel, C | 1 |
| Hill, AR | 1 |
| Mateo, F | 1 |
| Hudak, A | 1 |
| Anglaret, X | 1 |
| Saba, J | 1 |
| Perronne, C | 1 |
| Lacassin, F | 1 |
| Longuet, P | 1 |
| Leport, C | 1 |
| Vildé, JL | 1 |
| Jones, BE | 2 |
| Otaya, M | 1 |
| Antoniskis, D | 1 |
| Sian, S | 1 |
| Wang, F | 1 |
| Mercado, A | 1 |
| Davidson, PT | 1 |
| Barnes, PF | 1 |
| Greten, T | 1 |
| Hautmann, H | 1 |
| Trauner, A | 1 |
| Huber, RM | 1 |
| Fortún, J | 1 |
| Gómez-Mampaso, E | 1 |
| Navas, E | 1 |
| Hermida, JM | 1 |
| Antela, A | 1 |
| Guerrero, A | 1 |
| Günthard, H | 1 |
| Fuhrer, HP | 1 |
| Pfyffer, GE | 1 |
| Ruef, C | 1 |
| Lüthy, R | 1 |
| Kassim, S | 1 |
| Sassan-Morokro, M | 1 |
| Ackah, A | 1 |
| Abouya, LY | 1 |
| Digbeu, H | 1 |
| Yesso, G | 1 |
| Coulibaly, IM | 1 |
| Coulibaly, D | 1 |
| Whitaker, PJ | 1 |
| Doorly, R | 1 |
| Kennedy, N | 1 |
| Berger, L | 1 |
| Curram, J | 1 |
| Fox, R | 1 |
| Gutmann, J | 1 |
| Kisyombe, GM | 1 |
| Ngowi, FI | 1 |
| Ramsay, AR | 1 |
| Saruni, AO | 1 |
| Sam, N | 1 |
| Tillotson, G | 1 |
| Uiso, LO | 1 |
| Yates, M | 1 |
| Gillespie, SH | 1 |
| Chan, SP | 1 |
| Birnbaum, J | 1 |
| Rao, M | 1 |
| Steiner, P | 1 |
| Bergmann, KE | 1 |
| Cynamon, MH | 1 |
| Welch, JT | 1 |
| Choudhri, SH | 1 |
| Hawken, M | 1 |
| Gathua, S | 1 |
| Minyiri, GO | 1 |
| Watkins, W | 1 |
| Sahai, J | 1 |
| Sitar, DS | 1 |
| Aoki, FY | 1 |
| Long, R | 1 |
| Whalen, CC | 2 |
| Johnson, JL | 2 |
| Hom, DL | 2 |
| Mugyenyi, P | 1 |
| Mugerwa, RD | 2 |
| Ellner, JJ | 2 |
| Perlman, DC | 2 |
| El Sadr, WM | 1 |
| Heifets, LB | 1 |
| Nelson, ET | 2 |
| Matts, JP | 3 |
| Chirgwin, K | 1 |
| Salomon, N | 2 |
| Telzak, EE | 2 |
| Klein, O | 2 |
| Kreiswirth, BN | 1 |
| Musser, JM | 1 |
| Hafner, R | 3 |
| Jouveshomme, S | 1 |
| Dautzenberg, B | 1 |
| Halsey, NA | 2 |
| Coberly, JS | 1 |
| Desormeaux, J | 1 |
| Losikoff, P | 1 |
| Atkinson, J | 1 |
| Moulton, LH | 1 |
| Contave, M | 1 |
| Johnson, M | 1 |
| Davis, H | 1 |
| Geiter, L | 1 |
| Johnson, E | 1 |
| Boulos, R | 1 |
| Chaisson, RE | 4 |
| Mitchison, DA | 1 |
| el-Sadr, WM | 1 |
| Cohn, DL | 1 |
| Olibrice, M | 1 |
| Medard, F | 1 |
| Chirgwin, KD | 1 |
| Mildvan, D | 1 |
| Heifets, L | 1 |
| Colebunders, R | 1 |
| Florence, E | 1 |
| Kuaban, C | 1 |
| Bercion, R | 1 |
| Koula-Shiro, S | 1 |
| Coberly, J | 2 |
| Chaisson, R | 1 |
| Gordin, F | 2 |
| Rose, DN | 1 |
| Mwinga, A | 2 |
| Hosp, M | 2 |
| Godfrey-Faussett, P | 2 |
| Quigley, M | 1 |
| Mwaba, P | 1 |
| Mugala, BN | 1 |
| Nyirenda, O | 1 |
| Luo, N | 1 |
| Pobee, J | 1 |
| Elliott, AM | 1 |
| McAdam, KP | 2 |
| Porter, JD | 1 |
| Davies, GR | 1 |
| Connolly, C | 1 |
| Sturm, AW | 1 |
| Wilkinson, D | 1 |
| Sterling, TR | 1 |
| Alwood, K | 1 |
| Gachuhi, R | 1 |
| Coggin, W | 1 |
| Blazes, D | 1 |
| Bishai, WR | 1 |
| Miller, C | 1 |
| de Lourdes Garcia, M | 1 |
| Valdespino, JL | 1 |
| Schechter, M | 1 |
| Klukowicz, AJ | 1 |
| Barry, MA | 1 |
| O'Brien, RJ | 1 |
| Bwire, R | 1 |
| Borgdorff, MW | 1 |
| Sticht-Groh, V | 1 |
| Rieder, HL | 1 |
| Kawuma, HJ | 1 |
| Bretzel, G | 1 |
| Rüsch-Gerdes, S | 1 |
| Schaaf, HS | 1 |
| Gie, RP | 1 |
| van Rie, A | 1 |
| Seifart, HI | 1 |
| van Helden, PD | 1 |
| Cotton, MF | 1 |
| Quigley, MA | 1 |
| Lisse, I | 1 |
| Fuchs, D | 1 |
| Bowersox, J | 1 |
| James, JS | 1 |
| Torres, G | 1 |
| Moreno, S | 1 |
| Podzamczer, D | 1 |
| Blázquez, R | 1 |
| Iribarren, JA | 1 |
| Ferrer, E | 1 |
| Reparaz, J | 1 |
| Peña, JM | 1 |
| Cabrero, E | 1 |
| Usán, L | 1 |
| Kura, MM | 1 |
| Hira, SK | 1 |
| Mayanja, H | 1 |
| Mutuluuza Kityo, C | 1 |
| Nsubuga, P | 1 |
| Nakibali, JG | 1 |
| Loughlin, AM | 1 |
| Yun, H | 1 |
| Mugyenyi, PN | 1 |
| Vernon, A | 1 |
| Nolan, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes[NCT02129244] | 3,600 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons[NCT00351702] | Phase 3 | 650 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789] | 555 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | |||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000638] | 2,000 participants | Interventional | Completed | ||||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000636] | 2,000 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
4 reviews available for pyrazinamide and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Ag | 2007 |
[Esophagomediastinal fistulae as a rare complication of tuberculosis in an HIV-infected patient].
Topics: AIDS-Related Opportunistic Infections; Ciprofloxacin; Drug Therapy, Combination; Esophageal Fistula; | 1994 |
[Antitubercular chemotherapy].
Topics: Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Protocols; Drug | 1997 |
Failure of therapy for tuberculosis in human immunodeficiency virus infection.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Drug Therapy, Combi | 1992 |
16 trials available for pyrazinamide and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antitubercular Agents; Body Composition; Drug | 2008 |
Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Drug Eruptions; Drug Hypersensitivity; Dru | 1994 |
A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Etha | 1994 |
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul | 1995 |
Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Ciproflo | 1996 |
Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Biological Availability; Diarrh | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antibiotics, Antitubercular; Antituber | 1997 |
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; F | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antibiotics, Antitubercular; A | 1998 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 2001 |
Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antitubercular Age | 2001 |
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combi | 2001 |
32 other studies available for pyrazinamide and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Calibration; Chromatography, High Pres | 2020 |
[Renal mass in an HIV-positive elderly patient].
Topics: Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Combined Modality Therapy; Drug | 2009 |
[Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].
Topics: Abscess; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, High | 2011 |
Trial tests new combination of drugs to treat tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topi | 2012 |
Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Case-Control Studies; Coh | 2002 |
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 2002 |
Drug-resistant Mycobacterium tuberculosis among new tuberculosis patients, Yangon, Myanmar.
Topics: AIDS-Related Opportunistic Infections; Drug Resistance, Bacterial; Ethambutol; Humans; Isoniazid; My | 2003 |
Ocular tuberculosis in acquired immunodeficiency syndrome.
Topics: Abscess; Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lympho | 2006 |
[Therapy of tuberculosis in the adult].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Dose-Response Relationship, Dru | 1995 |
Transient exacerbation of tuberculous lymphadenitis during chemotherapy in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Ethambutol; Humans; Isoniazid; | 1994 |
Empiric antituberculosis treatment: benefits for earlier diagnosis and treatment of tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Body Weight; Drug Administratio | 1994 |
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Pro | 1994 |
[Tuberculous meningitis caused by resistant microorganisms. Therapeuticfailure in 2 patients with HIV infection and disseminated tuberculosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Microbial; Dru | 1994 |
[Disseminated tuberculosis with a multiresistant strain of Mycobacterium tuberculosis in an HIV-infected Swiss male].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Microbial; Dru | 1993 |
Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; AIDS-Related Opportunistic Infections; Antibiotics, | 1996 |
Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Esters; Humans; Microbial Sensitivity | 1996 |
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi | 1998 |
Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Developing Countries; Drug Therapy, Co | 1998 |
Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 1998 |
Prevention of tuberculosis in HIV-1.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Microbial; HIV-1; Hum | 1998 |
Short-term tuberculosis prophylaxis is effective in persons with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Humans; Isoniazid; Patient Compliance; | 1998 |
Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Chemical | 1998 |
Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cohort Studies; Drug Therapy, C | 1999 |
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 1999 |
Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance; Dr | 1999 |
Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?
Topics: AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Antibiotics, A | 2000 |
CPCRA researchers present OI studies at Vancouver.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Antifung | 1996 |
Medical advances with international impact.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antitubercular | 1998 |
A short two-drug regimen prevents active TB.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy | 1998 |
Short course preventive therapy for tuberculosis is successful in HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Clinical Trials as Topic; Drug Administration Schedule; Drug | 1998 |
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Con | 2001 |
Tuberculosis: guidelines changed for latent TB treatment.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Centers for Disease Control and Preven | 2001 |